TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03578523

Intervention type: OTHER
Intervention: 3 Tesla multiparametric MR
Description: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.

Intervention type: OTHER
Intervention: 3 Tesla multiparametric MR
Description: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.

Intervention type: OTHER
Intervention: renal histopathology scoring
Description: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)

Intervention type: OTHER
Intervention: renal histopathology scoring
Description: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)

Intervention type: BIOLOGICAL
Intervention: Blood and urine sampling
Description: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis

Intervention type: BIOLOGICAL
Intervention: Blood and urine sampling
Description: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis

Intervention type: BIOLOGICAL
Intervention: Iohexol clearance test
Description: Iohexol clearance to measure GFR within 1 week of the scan session

Intervention type: BIOLOGICAL
Intervention: Iohexol clearance test
Description: Iohexol clearance to measure GFR within 1 week of the scan session
Study: NCT02482233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENDD (NJOY)
Description: As described above.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRT (NicoDerm CQ)
Description: As described above.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone counseling
Description: Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telephone counseling
Description: Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief advice
Description: Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brief advice
Description: Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brochure
Description: A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brochure
Description: A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf
Study: NCT06037135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery. The research nurse, who did not participate in the study other than the management and preparation of the study medication, prepared 50mL of 0.9% normal saline for the control group and a mixture of dexmedetomidine 2 mL and 0.9% normal saline 48 mL (at a concentration of 4 μg/mL) for the dexmedetomidine group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline
Description: In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
Study: NCT01285258

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hysterectomy
Description: excluding the uterus with saving ovaries
Study: NCT02611232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victoza®
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
Study: NCT01985061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BX2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BX4-Suspended
Description: Suspended
Study: NCT01322958

Intervention type: DEVICE
Intervention: Pelvic Ultrasound
Description: Pelvic ultrasound performed by the emergency physician
Study: NCT00595218

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician behavior related to Patient Preference Survey
Description: Access to initial Patient preference survey results

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Preference Results
Description: Knowledge of Patient Preference Results
Study: NCT01111903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
Study: NCT01516788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototesting
Description: Single MED dose on Day 2
Study: NCT01326988

Intervention type: PROCEDURE
Intervention: Real-time ultrasound guided spinal anesthesia
Description: The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
Study: NCT03994146

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Syringe containing 40 ml of Sodium Chloride 9 mg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 9mg/mL
Description: Syringe containing 40 ml of Sodium Chloride 9 mg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery.
Study: NCT04164563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Even-Up
Description: Orthotic shoe lift worn on contralateral foot to increase leg length
Study: NCT01549730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Description: A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
Study: NCT00324038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buprenorphine transdermal system 5, 10 and 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine paracetamol
Description: combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
Study: NCT02401919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell-us Card
Description: Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
Study: NCT01109095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER.CAR CMV-specific CTLs
Description: HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:~* 1 x 10\^6/m\^2~* 3 x 10\^6/m\^2~* 1 x 10\^7/m\^2~* 3 x 10\^7/m\^2~* 1 x 10\^8/m\^2
Study: NCT01514903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP0908
Description: SINGLE DOSE , CROSS OVER

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: viagra
Description: single dose, cross over
Study: NCT01668212

Intervention type: PROCEDURE
Intervention: Doppler ultrasound
Description: Doppler Ultrasound
Study: NCT05478187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional visual cues - Control group
Description: 10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
Study: NCT00663715

Intervention type: OTHER
Intervention: Observation of the Sciatic Nerve
Description: Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
Study: NCT03134430

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Injection of Normal saline around peripheral nerve

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peripheral Nerve block
Description: Injection of local anesthetics around peripheral nerve
Study: NCT00217724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glutamine
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03936218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Goserelin (Test) Subcutaneously
Description: 10.8 mg, subcutaneously at every 3 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj. Zoladex (Reference) Subcutaneously
Description: 10.8 mg, Subcutaneously at every 3 month
Study: NCT04487899

Intervention type: DEVICE
Intervention: Analysis of heart rate variability
Description: The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).

Intervention type: DEVICE
Intervention: Analysis of heart rate variability
Description: The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).
Study: NCT02539784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System
Description: 3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
Study: NCT03968926

Intervention type: OTHER
Intervention: Arterial pressure management during circulatory support by VA-ECMO
Description: Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)
Study: NCT02270216

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: static hand grip exercise
Description: The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: static hand grip exercise
Description: The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cycling exercise
Description: The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7\*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes.
Study: NCT04305054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days
Study: NCT02840955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staphefekt SA.100

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04074031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound Therapy (Exablate® 4000 Type 1.1)
Description: The Exablate® 4000 Type 1.1 model designed for noninvasive ablation of brain tissue is an MRI-guided transcranial ultrasound system (MRgFUS). The goal of the Exablate Neuro system is to precisely guide the focus of the ultrasound energy on the target region. The focused ultrasound energy is then repeatedly transmitted to the target until the desired result is achieved. Targeting is performed using MRI acquired during treatment. The treatment process is constantly monitored by closed-loop thermal feedback in real time, under the supervision of the treating physician. Once targeting is complete, the treatment outcome is confirmed by MRI sequences immediately after treatment. The Exablate Neuro is compatible with Siemens 3 Tesla MRI.
Study: NCT02270216

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cycling exercise
Description: The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7\*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes.
Study: NCT03419104

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: preoperative walk test
Description: Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
Study: NCT04305054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vibostolimab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vibostolimab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab/Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days
Study: NCT01478828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: oral qd varying dose escalations/de-escalations
Study: NCT01713088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy
Study: NCT04305054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab/Pembrolizumab
Description: Administered via IV infusion at a specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: Administered via oral capsule at a specified dose on specified days
Study: NCT03585231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate access to novel messaging program intervention
Description: The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate access to standard of care messaging program intervention
Description: The immediate control intervention uses a standard of care messaging program for smoking cessation.
Study: NCT01713088

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: YOT (usual services)
Study: NCT01246713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen liquid formulation
Description: Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen solid formulation
Description: Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.